20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

PHASE2TerminatedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Schizophrenia
Interventions
DRUG

AMG 747

Three dose levels once-daily oral administration

DRUG

Placebo

Once-daily oral administration

Trial Locations (44)

10027

Research Site, New York

14215

Research Site, Buffalo

18503

Research Site, Scranton

20850

Research Site, Rockville

27710

Research Site, Durham

30029

Research Site, Nîmes

30328

Research Site, Atlanta

30450

Research Site, Ipoh

31250

Research Site, Ipoh

33018

Research Site, Hialeah

34741

Research Site, Kissimmee

38119

Research Site, Memphis

39100

Research Site, Dôle

39232

Research Site, Flowood

55100

Research Site, Kuala Lumpur

56000

Research Site, Kuala Lumpur

59100

Research Site, Kuala Lumpur

72211

Research Site, Little Rock

72764

Research Site, Springdale

75230

Research Site, Dallas

82013

Research Site, Montauban

90813

Research Site, Long Beach

92868

Research Site, Orange

94010

Research Site, Créteil

94612

Research Site, Oakland

08540

Research Site, Princeton

615 00

Research Site, Brno

779 00

Research Site, Olomouc

120 00

Research Site, Prague

190 00

Research Site, Prague

750 01

Research Site, Přerov

386 29

Research Site, Strakonice

85-096

Research Site, Bydgoszcz

86-200

Research Site, Chełmno

40-340

Research Site, Katowice

60-185

Research Site, Skorzewo

87-100

Research Site, Torun

09-300

Research Site, Żuromin

EN5 3DJ

Research Site, Barnet

EH10 5HF

Research Site, Edinburgh

SE5 8AF

Research Site, London

NR1 3RE

Research Site, Norwich

S10 3TH

Research Site, Sheffield

WA2 8WA

Research Site, Warrington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY